Academic Journal
Polyphenol‑based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review).
| Τίτλος: | Polyphenol‑based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review). |
|---|---|
| Συγγραφείς: | Zeng J; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Hu J; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Ma Z; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Zhu S; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Lv X; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Zhang L; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Shen M; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Li T; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China. |
| Πηγή: | Oncology reports [Oncol Rep] 2026 Oct; Vol. 56 (4). Date of Electronic Publication: 2026 Aug 14. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE |
| Imprint Name(s): | Publication: <2003->: Athens : D.A. Spandidos Original Publication: [Athens, Greece] : National Hellenic Research Foundation, 1994- |
| Ιατρικοί όροι (MeSH): | Polyphenols*/therapeutic use , Polyphenols*/pharmacology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology, Signal Transduction/drug effects ; Humans ; Female ; Animals ; Translational Research, Biomedical |
| Περίληψη: | Breast cancer (BC) comprises multiple molecular subtypes with distinct epidemiological, biological and therapeutic features. Although advances in diagnosis and systemic therapy have improved patient outcomes, therapeutic resistance, treatment‑related toxicity and disease recurrence remain major clinical challenges. Growing evidence suggests that plant‑derived polyphenols may influence BC progression through multiple biological mechanisms. These compounds can inhibit tumor‑cell proliferation, migration, angiogenesis, inflammation, epithelial‑mesenchymal transition and metastasis, while promoting apoptosis, autophagy, cell‑cycle arrest and tumor‑suppressive responses. Mechanistically, polyphenols may regulate several interconnected signaling pathways involved in BC development and progression, including PI3K/AKT/mTOR, p53, NF‑κB, STAT3, Wnt/β‑catenin and MAPK signaling. In addition to their direct effects on tumor cells, polyphenols may interact with the gut microbiome, which in turn influences polyphenol metabolism, estrogen homeostasis, immune regulation, inflammation and bioavailability. Probiotics, prebiotics and microbiota‑derived metabolites may further influence this polyphenol‑gut microbiome‑BC axis. Polyphenols have also been explored as adjuvant or supportive agents in combination with chemotherapy, endocrine therapy and radiotherapy, as well as in novel delivery systems designed to improve their bioavailability and therapeutic efficacy. However, most current evidence remains preclinical. Well‑designed clinical trials are therefore needed to define the optimal formulations, doses, safety profiles, pharmacokinetics and therapeutic relevance of polyphenol‑based interventions in BC. |
| References: | Int J Mol Sci. 2026 Mar 25;27(7):. (PMID: 41977169) Front Oncol. 2025 Jun 17;15:1617410. (PMID: 40599853) Clin Cancer Res. 2024 Mar 1;30(5):965-974. (PMID: 37847493) Drug Des Devel Ther. 2021 Jan 12;15:125-140. (PMID: 33469265) Cell Host Microbe. 2024 Jun 12;32(6):925-944.e10. (PMID: 38754417) Life Sci. 2021 Sep 1;280:119729. (PMID: 34146553) Photochem Photobiol Sci. 2025 Mar;24(3):451-465. (PMID: 40095354) Foods. 2021 Dec 20;10(12):. (PMID: 34945706) Mol Nutr Food Res. 2025 Aug;69(16):e70055. (PMID: 40190185) J Mater Chem B. 2026 Mar 11;14(10):3239-3254. (PMID: 41738466) Molecules. 2022 May 20;27(10):. (PMID: 35630763) Molecules. 2023 Mar 10;28(6):. (PMID: 36985507) Oncol Rep. 2021 Feb;45(2):717-727. (PMID: 33416150) Chem Biol Interact. 2026 Jan 5;423:111825. (PMID: 41232639) Pharmaceutics. 2022 Feb 15;14(2):. (PMID: 35214154) Int J Biol Macromol. 2021 Aug 31;185:134-152. (PMID: 34147524) Clin Imaging. 2026 Apr;132:110741. (PMID: 41671902) J Biochem Mol Toxicol. 2021 Feb;35(2):e22642. (PMID: 33058431) Arch Pharm (Weinheim). 2024 Oct;357(10):e2400261. (PMID: 38943449) Int Immunopharmacol. 2020 Jul;84:106535. (PMID: 32361569) Med Oncol. 2025 Dec 26;43(2):94. (PMID: 41452530) Sci Rep. 2024 Jan 17;14(1):1510. (PMID: 38233443) Life Sci. 2021 Jan 15;265:118787. (PMID: 33249095) Food Res Int. 2022 Nov;161:111800. (PMID: 36192946) Med Oncol. 2026 May 12;43(6):. (PMID: 42118362) Nanotheranostics. 2021 Jan 1;5(1):113-124. (PMID: 33391978) J Anim Sci. 2025 Jan 04;103:. (PMID: 40036370) Oncol Rep. 2024 Aug;52(2):. (PMID: 38940326) Discov Oncol. 2025 Aug 14;16(1):1554. (PMID: 40813507) Phytomedicine. 2026 Mar;152:157819. (PMID: 41638057) Fitoterapia. 2024 Jun;175:105927. (PMID: 38548028) Int J Mol Cell Med. 2021 Winter;10(1):11-22. (PMID: 34268250) Pharmaceuticals (Basel). 2026 Mar 30;19(4):. (PMID: 42075806) Appl Biochem Biotechnol. 2023 Apr;195(4):2687-2708. (PMID: 35262883) Cell Biochem Funct. 2024 Dec;42(8):e70014. (PMID: 39529484) Sci Rep. 2025 May 19;15(1):17279. (PMID: 40389522) Signal Transduct Target Ther. 2025 Feb 19;10(1):49. (PMID: 39966355) Cancer Invest. 2025 Mar;43(3):173-182. (PMID: 40145664) Bioorg Chem. 2024 Apr;145:107178. (PMID: 38359708) Food Res Int. 2024 Sep;192:114778. (PMID: 39147466) Support Care Cancer. 2020 Jul;28(7):3303-3311. (PMID: 31758326) Phytomedicine. 2020 May 23;76:153243. (PMID: 32535482) Int J Pharm. 2023 Oct 15;645:123392. (PMID: 37683979) Phytomedicine. 2020 Apr 18;70:153218. (PMID: 32335356) J Pharmacol Exp Ther. 2023 Feb;384(2):254-264. (PMID: 36456194) Breast Cancer Res Treat. 2024 May;205(1):61-73. (PMID: 38280052) J Toxicol Environ Health A. 2023 Nov 17;86(22):833-845. (PMID: 37668343) Biochem Biophys Res Commun. 2025 Jul 8;769:151942. (PMID: 40359763) Food Funct. 2024 May 7;15(9):4763-4772. (PMID: 38590256) Breast Cancer Res. 2024 Oct 25;26(1):147. (PMID: 39456028) J Environ Pathol Toxicol Oncol. 2022;41(3):33-43. (PMID: 35993954) J Pharm Pharmacol. 2024 May 3;76(5):499-513. (PMID: 37971302) Adv Mater. 2026 May;38(26):e18631. (PMID: 41934190) Mediators Inflamm. 2022 Jan 29;2022:2567150. (PMID: 35132306) Int Immunopharmacol. 2024 May 30;133:112069. (PMID: 38643710) Food Chem. 2024 May 15;440:138240. (PMID: 38150907) Int J Mol Sci. 2025 Jan 14;26(2):. (PMID: 39859369) Front Immunol. 2024 Mar 27;15:1366197. (PMID: 38601156) Int J Mol Sci. 2021 Sep 01;22(17):. (PMID: 34502426) Biochem Pharmacol. 2021 Oct;192:114717. (PMID: 34352281) Nutrients. 2021 Nov 04;13(11):. (PMID: 34836197) Mol Cell Biochem. 2022 Apr;477(4):1281-1293. (PMID: 35129780) Crit Rev Oncol Hematol. 2025 Nov;215:104879. (PMID: 40783076) BMC Complement Med Ther. 2024 Sep 4;24(1):329. (PMID: 39232773) Nanoscale. 2025 Feb 27;17(9):5033-5055. (PMID: 40013710) Clin Nutr ESPEN. 2022 Dec;52:158-168. (PMID: 36513449) Probiotics Antimicrob Proteins. 2024 Jun;16(3):829-844. (PMID: 37162668) Heliyon. 2024 May 24;10(11):e31925. (PMID: 38841445) Biomedicines. 2025 Apr 18;13(4):. (PMID: 40299687) Food Chem. 2024 Nov 15;458:140262. (PMID: 38944925) Phytomedicine. 2024 Jul 25;130:155560. (PMID: 38815404) ACS Nano. 2024 May 21;18(20):12917-12932. (PMID: 38720520) Diagn Pathol. 2024 Feb 16;19(1):35. (PMID: 38365810) Cell Biochem Biophys. 2025 Jun;83(2):2533-2546. (PMID: 39760839) Nutrients. 2021 Jan 19;13(1):. (PMID: 33477894) Mol Biol Rep. 2021 Dec;48(12):7733-7742. (PMID: 34637097) Heliyon. 2023 Nov 27;9(12):e22892. (PMID: 38058440) Breast Cancer Res Treat. 2020 Nov;184(1):107-113. (PMID: 32803636) Phytother Res. 2025 Nov;39(11):5006-5024. (PMID: 40898993) J Agric Food Chem. 2021 Dec 15;69(49):14849-14855. (PMID: 34870993) J Proteome Res. 2025 Apr 04;24(4):2096-2111. (PMID: 40108892) Mol Pharm. 2020 Apr 6;17(4):1415-1427. (PMID: 32159961) J Oncol Pharm Pract. 2025 Sep;31(6):965-976. (PMID: 39110237) Talanta. 2024 Jun 1;273:125938. (PMID: 38503125) Curr Nutr Rep. 2023 Mar;12(1):83-97. (PMID: 36746877) Crit Rev Food Sci Nutr. 2020;60(4):626-659. (PMID: 30614249) Mol Nutr Food Res. 2021 Jun;65(12):e2100163. (PMID: 33939887) Nutrients. 2021 Dec 28;14(1):. (PMID: 35011012) CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. (PMID: 39352042) Nutr J. 2018 Feb 27;17(1):34. (PMID: 29486772) Health Sci Rep. 2024 Sep 16;7(9):e70052. (PMID: 39286738) Mol Med Rep. 2020 Dec;22(6):4868-4876. (PMID: 33173974) Nat Commun. 2026 May 13;17(1):. (PMID: 42129171) Biochem Biophys Res Commun. 2024 Dec 20;739:150972. (PMID: 39541924) Int J Mol Sci. 2023 Nov 05;24(21):. (PMID: 37958959) Nutrients. 2023 Jan 06;15(2):. (PMID: 36678170) Gut Microbes. 2023 Jan-Dec;15(1):2236749. (PMID: 37559394) Acta Pharm Sin B. 2022 Feb;12(2):907-923. (PMID: 35256954) Nutrients. 2020 Mar 13;12(3):. (PMID: 32183060) Cancer Cell Int. 2026 Feb 12;26(1):. (PMID: 41680875) J Clin Oncol. 2020 May 1;38(13):1419-1428. (PMID: 32031879) J Colloid Interface Sci. 2024 Dec 15;676:974-988. (PMID: 39068841) Clin Nutr. 2021 Apr;40(4):2068-2077. (PMID: 33051045) |
| Contributed Indexing: | Keywords: adjuvant therapy; breast cancer; drug delivery; gut microbiome; polyphenols; signaling pathways |
| Substance Nomenclature: | 0 (Polyphenols) |
| Entry Date(s): | Date Created: 20260814 Date Completed: 20260814 Latest Revision: 20260907 |
| Update Code: | 20260907 |
| PubMed Central ID: | PMC13488138 |
| DOI: | 10.3892/or.2026.9176 |
| PMID: | 42596834 |
| Βάση Δεδομένων: | MEDLINE |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: cmedm DbLabel: MEDLINE An: 42596834 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Polyphenol‑based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Zeng+J%22">Zeng J</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.<br /><searchLink fieldCode="AU" term="%22Hu+J%22">Hu J</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.<br /><searchLink fieldCode="AU" term="%22Ma+Z%22">Ma Z</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.<br /><searchLink fieldCode="AU" term="%22Zhu+S%22">Zhu S</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.<br /><searchLink fieldCode="AU" term="%22Lv+X%22">Lv X</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.<br /><searchLink fieldCode="AU" term="%22Zhang+L%22">Zhang L</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.<br /><searchLink fieldCode="AU" term="%22Shen+M%22">Shen M</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.<br /><searchLink fieldCode="AU" term="%22Li+T%22">Li T</searchLink>; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229422756%22">Oncology reports</searchLink> [Oncol Rep] 2026 Oct; Vol. 56 (4). <i>Date of Electronic Publication: </i>2026 Aug 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: Language Label: Language Group: Lang Data: English – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22D%2EA%2E+Spandidos%22">D.A. Spandidos </searchLink><i>Country of Publication: </i>Greece <i>NLM ID: </i>9422756 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1791-2431 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221021335X%22">1021335X </searchLink><i>NLM ISO Abbreviation: </i>Oncol Rep <i>Subsets: </i>MEDLINE – Name: PublisherInfo Label: Imprint Name(s) Group: PubInfo Data: <i>Publication</i>: <2003->: Athens : D.A. Spandidos<br /><i>Original Publication</i>: [Athens, Greece] : National Hellenic Research Foundation, 1994- – Name: SubjectMESH Label: MeSH Terms Group: Su Data: <searchLink fieldCode="MM" term="%22Polyphenols%22">Polyphenols*</searchLink>/<searchLink fieldCode="MM" term="%22Polyphenols+therapeutic+use%22">therapeutic use</searchLink> <br /><searchLink fieldCode="MM" term="%22Polyphenols%22">Polyphenols*</searchLink>/<searchLink fieldCode="MM" term="%22Polyphenols+pharmacology%22">pharmacology</searchLink> <br /><searchLink fieldCode="MM" term="%22Breast+Neoplasms%22">Breast Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Breast+Neoplasms+drug+therapy%22">drug therapy</searchLink> <br /><searchLink fieldCode="MM" term="%22Breast+Neoplasms%22">Breast Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Breast+Neoplasms+pathology%22">pathology</searchLink><br /><searchLink fieldCode="MH" term="%22Signal+Transduction%22">Signal Transduction</searchLink>/<searchLink fieldCode="MH" term="%22Signal+Transduction+drug+effects%22">drug effects</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Female%22">Female</searchLink> ; <searchLink fieldCode="MH" term="%22Animals%22">Animals</searchLink> ; <searchLink fieldCode="MH" term="%22Translational+Research%2C+Biomedical%22">Translational Research, Biomedical</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Breast cancer (BC) comprises multiple molecular subtypes with distinct epidemiological, biological and therapeutic features. Although advances in diagnosis and systemic therapy have improved patient outcomes, therapeutic resistance, treatment‑related toxicity and disease recurrence remain major clinical challenges. Growing evidence suggests that plant‑derived polyphenols may influence BC progression through multiple biological mechanisms. These compounds can inhibit tumor‑cell proliferation, migration, angiogenesis, inflammation, epithelial‑mesenchymal transition and metastasis, while promoting apoptosis, autophagy, cell‑cycle arrest and tumor‑suppressive responses. Mechanistically, polyphenols may regulate several interconnected signaling pathways involved in BC development and progression, including PI3K/AKT/mTOR, p53, NF‑κB, STAT3, Wnt/β‑catenin and MAPK signaling. In addition to their direct effects on tumor cells, polyphenols may interact with the gut microbiome, which in turn influences polyphenol metabolism, estrogen homeostasis, immune regulation, inflammation and bioavailability. Probiotics, prebiotics and microbiota‑derived metabolites may further influence this polyphenol‑gut microbiome‑BC axis. Polyphenols have also been explored as adjuvant or supportive agents in combination with chemotherapy, endocrine therapy and radiotherapy, as well as in novel delivery systems designed to improve their bioavailability and therapeutic efficacy. However, most current evidence remains preclinical. Well‑designed clinical trials are therefore needed to define the optimal formulations, doses, safety profiles, pharmacokinetics and therapeutic relevance of polyphenol‑based interventions in BC. – Name: Ref Label: References Group: RefInfo Data: Int J Mol Sci. 2026 Mar 25;27(7):. (PMID: <searchLink fieldCode="PM" term="%2241977169%22">41977169)</searchLink><br />Front Oncol. 2025 Jun 17;15:1617410. (PMID: <searchLink fieldCode="PM" term="%2240599853%22">40599853)</searchLink><br />Clin Cancer Res. 2024 Mar 1;30(5):965-974. (PMID: <searchLink fieldCode="PM" term="%2237847493%22">37847493)</searchLink><br />Drug Des Devel Ther. 2021 Jan 12;15:125-140. (PMID: <searchLink fieldCode="PM" term="%2233469265%22">33469265)</searchLink><br />Cell Host Microbe. 2024 Jun 12;32(6):925-944.e10. (PMID: <searchLink fieldCode="PM" term="%2238754417%22">38754417)</searchLink><br />Life Sci. 2021 Sep 1;280:119729. (PMID: <searchLink fieldCode="PM" term="%2234146553%22">34146553)</searchLink><br />Photochem Photobiol Sci. 2025 Mar;24(3):451-465. (PMID: <searchLink fieldCode="PM" term="%2240095354%22">40095354)</searchLink><br />Foods. 2021 Dec 20;10(12):. (PMID: <searchLink fieldCode="PM" term="%2234945706%22">34945706)</searchLink><br />Mol Nutr Food Res. 2025 Aug;69(16):e70055. (PMID: <searchLink fieldCode="PM" term="%2240190185%22">40190185)</searchLink><br />J Mater Chem B. 2026 Mar 11;14(10):3239-3254. (PMID: <searchLink fieldCode="PM" term="%2241738466%22">41738466)</searchLink><br />Molecules. 2022 May 20;27(10):. (PMID: <searchLink fieldCode="PM" term="%2235630763%22">35630763)</searchLink><br />Molecules. 2023 Mar 10;28(6):. (PMID: <searchLink fieldCode="PM" term="%2236985507%22">36985507)</searchLink><br />Oncol Rep. 2021 Feb;45(2):717-727. (PMID: <searchLink fieldCode="PM" term="%2233416150%22">33416150)</searchLink><br />Chem Biol Interact. 2026 Jan 5;423:111825. (PMID: <searchLink fieldCode="PM" term="%2241232639%22">41232639)</searchLink><br />Pharmaceutics. 2022 Feb 15;14(2):. (PMID: <searchLink fieldCode="PM" term="%2235214154%22">35214154)</searchLink><br />Int J Biol Macromol. 2021 Aug 31;185:134-152. (PMID: <searchLink fieldCode="PM" term="%2234147524%22">34147524)</searchLink><br />Clin Imaging. 2026 Apr;132:110741. (PMID: <searchLink fieldCode="PM" term="%2241671902%22">41671902)</searchLink><br />J Biochem Mol Toxicol. 2021 Feb;35(2):e22642. (PMID: <searchLink fieldCode="PM" term="%2233058431%22">33058431)</searchLink><br />Arch Pharm (Weinheim). 2024 Oct;357(10):e2400261. (PMID: <searchLink fieldCode="PM" term="%2238943449%22">38943449)</searchLink><br />Int Immunopharmacol. 2020 Jul;84:106535. (PMID: <searchLink fieldCode="PM" term="%2232361569%22">32361569)</searchLink><br />Med Oncol. 2025 Dec 26;43(2):94. (PMID: <searchLink fieldCode="PM" term="%2241452530%22">41452530)</searchLink><br />Sci Rep. 2024 Jan 17;14(1):1510. (PMID: <searchLink fieldCode="PM" term="%2238233443%22">38233443)</searchLink><br />Life Sci. 2021 Jan 15;265:118787. (PMID: <searchLink fieldCode="PM" term="%2233249095%22">33249095)</searchLink><br />Food Res Int. 2022 Nov;161:111800. (PMID: <searchLink fieldCode="PM" term="%2236192946%22">36192946)</searchLink><br />Med Oncol. 2026 May 12;43(6):. (PMID: <searchLink fieldCode="PM" term="%2242118362%22">42118362)</searchLink><br />Nanotheranostics. 2021 Jan 1;5(1):113-124. (PMID: <searchLink fieldCode="PM" term="%2233391978%22">33391978)</searchLink><br />J Anim Sci. 2025 Jan 04;103:. (PMID: <searchLink fieldCode="PM" term="%2240036370%22">40036370)</searchLink><br />Oncol Rep. 2024 Aug;52(2):. (PMID: <searchLink fieldCode="PM" term="%2238940326%22">38940326)</searchLink><br />Discov Oncol. 2025 Aug 14;16(1):1554. (PMID: <searchLink fieldCode="PM" term="%2240813507%22">40813507)</searchLink><br />Phytomedicine. 2026 Mar;152:157819. (PMID: <searchLink fieldCode="PM" term="%2241638057%22">41638057)</searchLink><br />Fitoterapia. 2024 Jun;175:105927. (PMID: <searchLink fieldCode="PM" term="%2238548028%22">38548028)</searchLink><br />Int J Mol Cell Med. 2021 Winter;10(1):11-22. (PMID: <searchLink fieldCode="PM" term="%2234268250%22">34268250)</searchLink><br />Pharmaceuticals (Basel). 2026 Mar 30;19(4):. (PMID: <searchLink fieldCode="PM" term="%2242075806%22">42075806)</searchLink><br />Appl Biochem Biotechnol. 2023 Apr;195(4):2687-2708. (PMID: <searchLink fieldCode="PM" term="%2235262883%22">35262883)</searchLink><br />Cell Biochem Funct. 2024 Dec;42(8):e70014. (PMID: <searchLink fieldCode="PM" term="%2239529484%22">39529484)</searchLink><br />Sci Rep. 2025 May 19;15(1):17279. (PMID: <searchLink fieldCode="PM" term="%2240389522%22">40389522)</searchLink><br />Signal Transduct Target Ther. 2025 Feb 19;10(1):49. (PMID: <searchLink fieldCode="PM" term="%2239966355%22">39966355)</searchLink><br />Cancer Invest. 2025 Mar;43(3):173-182. (PMID: <searchLink fieldCode="PM" term="%2240145664%22">40145664)</searchLink><br />Bioorg Chem. 2024 Apr;145:107178. (PMID: <searchLink fieldCode="PM" term="%2238359708%22">38359708)</searchLink><br />Food Res Int. 2024 Sep;192:114778. (PMID: <searchLink fieldCode="PM" term="%2239147466%22">39147466)</searchLink><br />Support Care Cancer. 2020 Jul;28(7):3303-3311. (PMID: <searchLink fieldCode="PM" term="%2231758326%22">31758326)</searchLink><br />Phytomedicine. 2020 May 23;76:153243. (PMID: <searchLink fieldCode="PM" term="%2232535482%22">32535482)</searchLink><br />Int J Pharm. 2023 Oct 15;645:123392. (PMID: <searchLink fieldCode="PM" term="%2237683979%22">37683979)</searchLink><br />Phytomedicine. 2020 Apr 18;70:153218. (PMID: <searchLink fieldCode="PM" term="%2232335356%22">32335356)</searchLink><br />J Pharmacol Exp Ther. 2023 Feb;384(2):254-264. (PMID: <searchLink fieldCode="PM" term="%2236456194%22">36456194)</searchLink><br />Breast Cancer Res Treat. 2024 May;205(1):61-73. (PMID: <searchLink fieldCode="PM" term="%2238280052%22">38280052)</searchLink><br />J Toxicol Environ Health A. 2023 Nov 17;86(22):833-845. (PMID: <searchLink fieldCode="PM" term="%2237668343%22">37668343)</searchLink><br />Biochem Biophys Res Commun. 2025 Jul 8;769:151942. (PMID: <searchLink fieldCode="PM" term="%2240359763%22">40359763)</searchLink><br />Food Funct. 2024 May 7;15(9):4763-4772. (PMID: <searchLink fieldCode="PM" term="%2238590256%22">38590256)</searchLink><br />Breast Cancer Res. 2024 Oct 25;26(1):147. (PMID: <searchLink fieldCode="PM" term="%2239456028%22">39456028)</searchLink><br />J Environ Pathol Toxicol Oncol. 2022;41(3):33-43. (PMID: <searchLink fieldCode="PM" term="%2235993954%22">35993954)</searchLink><br />J Pharm Pharmacol. 2024 May 3;76(5):499-513. (PMID: <searchLink fieldCode="PM" term="%2237971302%22">37971302)</searchLink><br />Adv Mater. 2026 May;38(26):e18631. (PMID: <searchLink fieldCode="PM" term="%2241934190%22">41934190)</searchLink><br />Mediators Inflamm. 2022 Jan 29;2022:2567150. (PMID: <searchLink fieldCode="PM" term="%2235132306%22">35132306)</searchLink><br />Int Immunopharmacol. 2024 May 30;133:112069. (PMID: <searchLink fieldCode="PM" term="%2238643710%22">38643710)</searchLink><br />Food Chem. 2024 May 15;440:138240. (PMID: <searchLink fieldCode="PM" term="%2238150907%22">38150907)</searchLink><br />Int J Mol Sci. 2025 Jan 14;26(2):. (PMID: <searchLink fieldCode="PM" term="%2239859369%22">39859369)</searchLink><br />Front Immunol. 2024 Mar 27;15:1366197. (PMID: <searchLink fieldCode="PM" term="%2238601156%22">38601156)</searchLink><br />Int J Mol Sci. 2021 Sep 01;22(17):. (PMID: <searchLink fieldCode="PM" term="%2234502426%22">34502426)</searchLink><br />Biochem Pharmacol. 2021 Oct;192:114717. (PMID: <searchLink fieldCode="PM" term="%2234352281%22">34352281)</searchLink><br />Nutrients. 2021 Nov 04;13(11):. (PMID: <searchLink fieldCode="PM" term="%2234836197%22">34836197)</searchLink><br />Mol Cell Biochem. 2022 Apr;477(4):1281-1293. (PMID: <searchLink fieldCode="PM" term="%2235129780%22">35129780)</searchLink><br />Crit Rev Oncol Hematol. 2025 Nov;215:104879. (PMID: <searchLink fieldCode="PM" term="%2240783076%22">40783076)</searchLink><br />BMC Complement Med Ther. 2024 Sep 4;24(1):329. (PMID: <searchLink fieldCode="PM" term="%2239232773%22">39232773)</searchLink><br />Nanoscale. 2025 Feb 27;17(9):5033-5055. (PMID: <searchLink fieldCode="PM" term="%2240013710%22">40013710)</searchLink><br />Clin Nutr ESPEN. 2022 Dec;52:158-168. (PMID: <searchLink fieldCode="PM" term="%2236513449%22">36513449)</searchLink><br />Probiotics Antimicrob Proteins. 2024 Jun;16(3):829-844. (PMID: <searchLink fieldCode="PM" term="%2237162668%22">37162668)</searchLink><br />Heliyon. 2024 May 24;10(11):e31925. (PMID: <searchLink fieldCode="PM" term="%2238841445%22">38841445)</searchLink><br />Biomedicines. 2025 Apr 18;13(4):. (PMID: <searchLink fieldCode="PM" term="%2240299687%22">40299687)</searchLink><br />Food Chem. 2024 Nov 15;458:140262. (PMID: <searchLink fieldCode="PM" term="%2238944925%22">38944925)</searchLink><br />Phytomedicine. 2024 Jul 25;130:155560. (PMID: <searchLink fieldCode="PM" term="%2238815404%22">38815404)</searchLink><br />ACS Nano. 2024 May 21;18(20):12917-12932. (PMID: <searchLink fieldCode="PM" term="%2238720520%22">38720520)</searchLink><br />Diagn Pathol. 2024 Feb 16;19(1):35. (PMID: <searchLink fieldCode="PM" term="%2238365810%22">38365810)</searchLink><br />Cell Biochem Biophys. 2025 Jun;83(2):2533-2546. (PMID: <searchLink fieldCode="PM" term="%2239760839%22">39760839)</searchLink><br />Nutrients. 2021 Jan 19;13(1):. (PMID: <searchLink fieldCode="PM" term="%2233477894%22">33477894)</searchLink><br />Mol Biol Rep. 2021 Dec;48(12):7733-7742. (PMID: <searchLink fieldCode="PM" term="%2234637097%22">34637097)</searchLink><br />Heliyon. 2023 Nov 27;9(12):e22892. (PMID: <searchLink fieldCode="PM" term="%2238058440%22">38058440)</searchLink><br />Breast Cancer Res Treat. 2020 Nov;184(1):107-113. (PMID: <searchLink fieldCode="PM" term="%2232803636%22">32803636)</searchLink><br />Phytother Res. 2025 Nov;39(11):5006-5024. (PMID: <searchLink fieldCode="PM" term="%2240898993%22">40898993)</searchLink><br />J Agric Food Chem. 2021 Dec 15;69(49):14849-14855. (PMID: <searchLink fieldCode="PM" term="%2234870993%22">34870993)</searchLink><br />J Proteome Res. 2025 Apr 04;24(4):2096-2111. (PMID: <searchLink fieldCode="PM" term="%2240108892%22">40108892)</searchLink><br />Mol Pharm. 2020 Apr 6;17(4):1415-1427. (PMID: <searchLink fieldCode="PM" term="%2232159961%22">32159961)</searchLink><br />J Oncol Pharm Pract. 2025 Sep;31(6):965-976. (PMID: <searchLink fieldCode="PM" term="%2239110237%22">39110237)</searchLink><br />Talanta. 2024 Jun 1;273:125938. (PMID: <searchLink fieldCode="PM" term="%2238503125%22">38503125)</searchLink><br />Curr Nutr Rep. 2023 Mar;12(1):83-97. (PMID: <searchLink fieldCode="PM" term="%2236746877%22">36746877)</searchLink><br />Crit Rev Food Sci Nutr. 2020;60(4):626-659. (PMID: <searchLink fieldCode="PM" term="%2230614249%22">30614249)</searchLink><br />Mol Nutr Food Res. 2021 Jun;65(12):e2100163. (PMID: <searchLink fieldCode="PM" term="%2233939887%22">33939887)</searchLink><br />Nutrients. 2021 Dec 28;14(1):. (PMID: <searchLink fieldCode="PM" term="%2235011012%22">35011012)</searchLink><br />CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. (PMID: <searchLink fieldCode="PM" term="%2239352042%22">39352042)</searchLink><br />Nutr J. 2018 Feb 27;17(1):34. (PMID: <searchLink fieldCode="PM" term="%2229486772%22">29486772)</searchLink><br />Health Sci Rep. 2024 Sep 16;7(9):e70052. (PMID: <searchLink fieldCode="PM" term="%2239286738%22">39286738)</searchLink><br />Mol Med Rep. 2020 Dec;22(6):4868-4876. (PMID: <searchLink fieldCode="PM" term="%2233173974%22">33173974)</searchLink><br />Nat Commun. 2026 May 13;17(1):. (PMID: <searchLink fieldCode="PM" term="%2242129171%22">42129171)</searchLink><br />Biochem Biophys Res Commun. 2024 Dec 20;739:150972. (PMID: <searchLink fieldCode="PM" term="%2239541924%22">39541924)</searchLink><br />Int J Mol Sci. 2023 Nov 05;24(21):. (PMID: <searchLink fieldCode="PM" term="%2237958959%22">37958959)</searchLink><br />Nutrients. 2023 Jan 06;15(2):. (PMID: <searchLink fieldCode="PM" term="%2236678170%22">36678170)</searchLink><br />Gut Microbes. 2023 Jan-Dec;15(1):2236749. (PMID: <searchLink fieldCode="PM" term="%2237559394%22">37559394)</searchLink><br />Acta Pharm Sin B. 2022 Feb;12(2):907-923. (PMID: <searchLink fieldCode="PM" term="%2235256954%22">35256954)</searchLink><br />Nutrients. 2020 Mar 13;12(3):. (PMID: <searchLink fieldCode="PM" term="%2232183060%22">32183060)</searchLink><br />Cancer Cell Int. 2026 Feb 12;26(1):. (PMID: <searchLink fieldCode="PM" term="%2241680875%22">41680875)</searchLink><br />J Clin Oncol. 2020 May 1;38(13):1419-1428. (PMID: <searchLink fieldCode="PM" term="%2232031879%22">32031879)</searchLink><br />J Colloid Interface Sci. 2024 Dec 15;676:974-988. (PMID: <searchLink fieldCode="PM" term="%2239068841%22">39068841)</searchLink><br />Clin Nutr. 2021 Apr;40(4):2068-2077. (PMID: <searchLink fieldCode="PM" term="%2233051045%22">33051045)</searchLink> – Name: SubjectMinor Label: Contributed Indexing Group: Data: <i>Keywords: </i>adjuvant therapy; breast cancer; drug delivery; gut microbiome; polyphenols; signaling pathways – Name: NumberCAS Label: Substance Nomenclature Group: ID Data: 0 (Polyphenols) – Name: DateEntry Label: Entry Date(s) Group: Date Data: <i>Date Created: </i>20260814 <i>Date Completed: </i>20260814 <i>Latest Revision: </i>20260907 – Name: DateUpdate Label: Update Code Group: Date Data: 20260907 – Name: PubmedCentralID Label: PubMed Central ID Group: ID Data: PMC13488138 – Name: DOI Label: DOI Group: ID Data: 10.3892/or.2026.9176 – Name: AN Label: PMID Group: ID Data: 42596834 |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=42596834 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3892/or.2026.9176 Languages: – Code: eng Text: English Subjects: – SubjectFull: Signal Transduction drug effects Type: general – SubjectFull: Humans Type: general – SubjectFull: Female Type: general – SubjectFull: Animals Type: general – SubjectFull: Translational Research, Biomedical Type: general – SubjectFull: Polyphenols therapeutic use Type: general – SubjectFull: Polyphenols pharmacology Type: general – SubjectFull: Breast Neoplasms drug therapy Type: general – SubjectFull: Breast Neoplasms pathology Type: general Titles: – TitleFull: Polyphenol‑based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zeng J – PersonEntity: Name: NameFull: Hu J – PersonEntity: Name: NameFull: Ma Z – PersonEntity: Name: NameFull: Zhu S – PersonEntity: Name: NameFull: Lv X – PersonEntity: Name: NameFull: Zhang L – PersonEntity: Name: NameFull: Shen M – PersonEntity: Name: NameFull: Li T IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2026 Oct Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1791-2431 Numbering: – Type: volume Value: 56 – Type: issue Value: 4 Titles: – TitleFull: Oncology reports Type: main |
| ResultId | 1 |